Facial Paralysis: The increasing rate of infections and inflammation of facial nerves are likely to drive the growth of the global market at a CAGR of 6.5%

Pune, India, May 2018 /MRFR Press Release/- Market Research Future (MRFR) announces the publication of its research report – Global Facial Paralysis Market, 2018–2023

Market Highlights

Facial paralysis is a restriction of the facial movement due to nerve damage. Facial nerve paralysis is characterized by unilateral facial weakness. Some other symptoms include loss of taste, hyperacusis, and decreased salivation and tear secretion.

The global facial paralysis market is expected to register a CAGR of 6.5% during the forecast period.

Regional Analysis

The Americas dominates the global facial paralysis market owing to increasing cardiovascular disorders, which eventually leads to the increasing patient population. Additionally, increasing cardiovascular disorder rate is likely to enhance the growth of facial paralysis in the North American region. According to the American Heart Association, 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, in 2015, around USD 3.2 trillion were spend in healthcare expenditure in the U.S according to the Center for Disease Control and Prevention. Similarly, in 2015, 1.3% of the U.S. adults were diagnosed with inflammation of facial nerves.

Europe accounts for the second largest market due to increasing cardiovascular disorders and increasing infections. Additionally, the increasing government support and improving healthcare infrastructure along with increasing facial inflammations are driving the growth of the facial paralysis market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to lead to the increasing patient population. These factors are likely to drive the growth of the facial paralysis market.

Asia Pacific is the fastest growing market for facial paralysis whose growth is attributed to the rising population and increasing standard of living. Additionally, the increasing healthcare spending and the improved standard of living are likely to drive the growth of the market. India and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure in these regions and the increasing demand for diagnostic services.

On the other hand, the Middle East and Africa is expected to witness a gentle growth due to limited access to the healthcare industry and affordability issues among the population. In the Middle East, the growth of the market is driven by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases.

Access Report @ https://www.marketresearchfuture.com/reports/facial-paralysis-market-5942

Segmentation

The global facial paralysis market is segmented on the basis of treatment, diagnosis, type, and end-user.

On the basis of type, the market is segmented into, Ramsay Hunt Syndrome, Bell’s Palsy, and Lyme Disease.

On the basis of diagnosis, the market is segmented into electromyography, computerized tomography, and magnetic resonance imaging.

 On the basis of treatment, the market is segmented into medications, physical therapy, and surgery.

 On the basis of medication, the market is further sub-segmented into corticosteroids and antiviral drugs. 

On the basis of end-user, the market is segmented into hospitals and clinics, specialty centers, and research centers.

Key Players

Some of the key players in the facial paralysis market are, Boston Scientific, BioControl Medical, Cerebomed, Cyberonics, Astellas Pharma Inc., Sucampo Pharmaceuticals, Inc., and Novartis AG, among others.